BROAD SPECTRUM BETA-LACTAMASE INHIBITORS

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: PHS2001-2
Agency Tracking Number: 1R41AI048997-01
Amount: $160,232.00
Phase: Phase I
Program: STTR
Awards Year: 2001
Solitcitation Year: N/A
Solitcitation Topic Code: N/A
Solitcitation Number: N/A
Small Business Information
ALAMX, LLC
101 N WILMOT RD, STE 600, TUCSON, AZ 85711-3335, TUCSON, AZ, 85711
Duns: N/A
Hubzone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 JOHN BUYNAK
 (214) 768-2484
 JBUYNAK@MAIL.SMU.EDU
Business Contact
Phone: (520) 748-4465
Email: RCT2CPM@AOL.COM
Research Institution
 SOUTHERN METHODIST UNIVERSITY
 SOUTHERN METHODIST UNIVERSITY
DALLAS, TX, 76954
 Nonprofit college or university
Abstract
DESCRIPTION (Adapted from the application): Penicillin-resistant bacteria pose a serious threat to human welfare. This project will generate new products designed to defeat resistant microorganisms. The most prevalent cause of bacterial resistance involves the destruction of the antibiotic with the enzyme B-lactamase. There are more than 255 known B-lactamases, which have been grouped into four classes: A through D. Historically, class A has been the most clinically important. However, the incidence of class C-mediated infections has increased dramatically in the past decade. Often such resistant infections can be defeated through the co-administration of an antibiotic and a B-lactamase inhibitor. However, current commercial B-lactamase inhibitors are effective only against class A enzymes. We have now identified and patented lead compounds which are simultaneously effective against both class A and class C B-lactamases. This project will develop those leads into viable commercial products. Collaborations with a number of academic researchers and pharmaceutical companies are in place, allowing access to representative B-lactamases as well as microbiological evaluations of these inhibitors. The objective is to develop products which have a broader spectrum than commercial antibiotic/inhibitor combinations. This will include either better overall activity or better activity against a subclass of clinically important organisms not targeted by current commercial products. PROPOSED COMMERCIAL APPLICATION: These inhibitors can be combined with the commercial beta-lactam antibiotic to broaden the spectrum of the antibiotic.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government